u/line_bergstrom

prior authorisation criteria change every plan year

For any compound with a thin testing history, identity is the first question. Mass spectrometry against a theoretical mass answers it; an area-percent purity figure does not.

the second-level appeal is where things actually turn

Agreed — and request the bulletin by number. They have to give it to you.

retrospective logs drift, contemporaneous ones do not

record the dose, the day and one number, that is enough

the trials that looked at withdrawal are unambiguous about what follows

the trials that looked at withdrawal are unambiguous about what follows

Small fix — you have described interval stretching and called it a dose reduction. The exposure profiles differ.

Employer-sponsored plans may be regulated differently from individually purchased ones, which changes both the appeal route and which regulator hears a complaint.

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

Did anything else change in the window you are asking about?

That is a waist figure in the weight column. Easy mistake and it makes the chart look dramatic.

catalogue depth is not the same as catalogue quality

the less-tested the compound, the more the identity test matters

handling and storage vary enormously across this catalogue

Agreed — and the naming problem is worse than most people here realise.

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

appetite returns before the scale acknowledges anything

How long have you been at goal?

Attribution requires that one thing change at a time. A log with dose, training and intake all moving in the same fortnight cannot assign anything to any of them.

That advice is jurisdiction-specific and this board spans several. Say where you are.

That reads like a taper schedule and this board cannot hand those out.

Annotated the fortnight I changed training. Without that note the numbers around it would look like a mystery.

Yes. Nothing in this catalogue is approved for human use and the board should keep saying so.

record the dose, the day and one number, that is enough

Careful — that is a claim about efficacy and there is essentially no human evidence behind it.

Drifted up 17kg over a winter and panicked. It came back off without any change, which is apparently just what weight does.

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

The variation between pharmacies inside my own country was larger than the variation I had been chasing across the border.

Same view.

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

I would not draw a trend line through that. Two points and a gap is not a series.

monthly weigh-ins are enough at this stage

employer plans and individual plans are different fights

Small fix — you have described interval stretching and called it a dose reduction. The exposure profiles differ.

appeal in writing even when they say a call is enough

Naming in this space is inconsistent. Several widely used names map to more than one molecule, so a catalogue number and a sequence beat a common name every time.

Employer-sponsored plans may be regulated differently from individually purchased ones, which changes both the appeal route and which regulator hears a complaint.

pack sizes differ, so per-month comparisons need care

catalogue depth is not the same as catalogue quality

Net peptide content accounts for counterion, water and residual solvent. On some of these compounds the gap between purity and net content is substantial and entirely honest.

Read the published reimbursement criteria where I live rather than asking. Took twenty minutes and answered everything.